Fig. 1 · Structure
Documents & Downloads
SHR-1701
PD-L1/TGF β Fusion Protein
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein that targets programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β). This compound is designed to enhance anti-tumor immunity by concurrently inhibiting immune checkpoint pathways and modulating the tumor microenvironment. SHR-1701 is valuable for research applications focused on cancer immunotherapy and the modulation of TGF-β signaling in various malignancies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Ligand / Binder |
| CAS Number | 2891860-17-4 |
| Applications | PD-L1/TGF β Fusion Protein |
| Molecular Weight | 174.61 kDa |
| Synonyms | Retlirafusp alfa |
| SMILES | S[R1701] |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.